Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab for Idiosyncratic Facial Pain
NCT04249427Phase 4Completed
- Start
- Feb 2021
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Facial pain comparing Erenumab with Placebo (2 arms). Primary endpoint: Change in Mean Number of Days Per Month With Significant Mid-facial Pain or Pressure at 6 months. Started Feb 2021; status: completed.
02
Drugs
erenumab
03
Conditions
Facial pain
Beyond the preview
Go deeper on NCT04249427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04249427.